IRCCS Azienda Ospedaliero-Universitaria di Bologna

Liposomal Amphotericin B Shows Comparable Efficacy to Triazoles in Invasive Aspergillosis Treatment

- A multicenter retrospective study of 401 patients found that liposomal amphotericin B achieved similar 90-day survival rates to triazoles in treating invasive aspergillosis. - The study revealed no statistically significant difference in mortality between the two treatment approaches, with 90-day survival rates of 58.8% for triazoles and 53.3% for liposomal amphotericin B. - Treatment modification was more common with liposomal amphotericin B, with 62.9% of patients switching therapy at a median of 10 days compared to 15.5% in the triazole group. - The findings suggest liposomal amphotericin B represents a viable alternative to standard triazole therapy, particularly for high-risk patients with drug resistance concerns.